Oncologie

, Volume 9, Issue 12, pp 842–847 | Cite as

Allogreffe de cellules souches hématopoïétiques avec conditionnement à intensité réduite: situation en 2007 et perspectives

Original
  • 36 Downloads

Résumé

L’allogreffe de cellules souches hématopoïétiques (allo-CSH) est une thérapeutique curative dans les hémopathies malignes. Cependant, du fait d’une toxicité rédhibitoire, l’utilisation de l’allo-CSH, notamment chez des patients âgés, ou chez des patients avec des comorbidités, reste limitée. La démonstration du rôle primordial de l’effet immunologique dans le contrôle de la maladie tumorale en post-allogreffe, a permis d’ouvrir la voie à l’utilisation des conditionnements à intensité réduite, qui privilégient la composante immunosuppressive à la composante chimiothérapique du conditionnement. L’objectif de cette revue est de faire le point sur cette stratégie thérapeutique en mettant l’accent sur les acquis cliniques actuels, les limitations et les perspectives futures.

Motes clés

Allogreffe de cellules souches Conditionnement à intensité réduite Immunothérapie 

Reduced intensity allogeneic stem cell transplantation: current status (2007) and perspectives

Abstract

Allogeneic hematopoietic stem cell transplantation is a curative treatment for different hematological malignancies. However, because of a high rate of transplant-related mortality, the use of allo-CSH is limited in elderly patients or in patients with comorbidities. The demonstration of the major role of the immune system in disease control after allogeneic transplantation paved the way for the development of reduced intensity conditionings that favour the immunosuppressive component of the conditioning rather than the cytoreductive one. The aim of this review is to synthesize the available research evidence in this field, focusing on current clinical achievements, limitations and future perspectives.

Keywords

Allogeneic stem transplantation Reduced intensity conditioning Immunotherapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Alyea EP, Kim HT, Ho V, et al. (2005) Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 105: 1810–1814PubMedCrossRefGoogle Scholar
  2. 2.
    Blaise D, Vey N, Faucher C, et al. (2007) Current status of reduced intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 92: 533–541PubMedCrossRefGoogle Scholar
  3. 3.
    Bruno B, Rotta M, Patriarca F, et al. (2007) A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 356: 1110–1120PubMedCrossRefGoogle Scholar
  4. 4.
    Childs R, Clave E, Contentin N, et al. (1999) Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 94: 3234–3241PubMedGoogle Scholar
  5. 5.
    Childs RW, Clave E, Tisdale J, et al. (1999) Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft versus tumor effect. J Clin Oncol 17: 2044–2049PubMedGoogle Scholar
  6. 6.
    Corradini P, Tarella C, Olivieri A, et al. (2002) Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 99: 75–82PubMedCrossRefGoogle Scholar
  7. 7.
    de Lima M, Anagnostopoulos A, Munsell M, et al. (2004) Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 104: 865–872PubMedCrossRefGoogle Scholar
  8. 8.
    Gale RP, Horowitz MM, Ash RC, et al. (1994) Identical-twin bone marrow transplats for leukemia. Ann Intern Med 120: 646–652PubMedGoogle Scholar
  9. 9.
    Giralt S, Thall PF, Khouri I, et al. (2001) Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97: 631–637PubMedCrossRefGoogle Scholar
  10. 10.
    Girgis M, Hallemeier C, Blum W, et al. (2005) Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide. Blood 105: 3035–3041PubMedCrossRefGoogle Scholar
  11. 11.
    Mohty M, Jacot W, Faucher C, et al. (2003) Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia 17: 2168–2177PubMedCrossRefGoogle Scholar
  12. 12.
    Hegenbart U, Niederwieser D, Sandmaier BM, et al. (2006) Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 24: 444–453PubMedCrossRefGoogle Scholar
  13. 13.
    Ho AY, Pagliuca A, Kenyon M, et al. (2004) Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 104: 1616–1623PubMedCrossRefGoogle Scholar
  14. 14.
    Holler E, Kolb HJ, Mittermuller J, et al. (1995) Modulation of acute graft versus host disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood 86: 890–899PubMedGoogle Scholar
  15. 15.
    Khouri IF, Saliba RM, Giralt SA, et al. (2001) Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 98: 3595–3599PubMedCrossRefGoogle Scholar
  16. 16.
    Kolb HJ, Schattenberg A, Goldman JM, et al. (1995) Graft versus leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86: 2041–2050PubMedGoogle Scholar
  17. 17.
    Kottaridis PD, Milligan DW, Chopra R, et al. (2000) In vivo CAMPATH-1H prevents graft versus host disease following nonmyeloablative stem cell transplantation. Blood 96: 2419–2525PubMedGoogle Scholar
  18. 18.
    Kroger N, Perez-Simon JA, Myint H, et al. (2004) Relapse to prior autograft and chronic graft versus host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 10: 698–708PubMedCrossRefGoogle Scholar
  19. 19.
    Lowsky R, Takahashi T, Liu YP, et al. (2005) Protective conditioning for acute graft versus host disease. N Engl J Med 353: 1321–1331PubMedCrossRefGoogle Scholar
  20. 20.
    Maraninchi D, Gluckman E, Blaise D, et al. (1987) Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet 2: 175–178PubMedCrossRefGoogle Scholar
  21. 21.
    Martino R, Caballero MD, Canals C, et al. (2001) Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. Br J Haematol 115: 653–659PubMedCrossRefGoogle Scholar
  22. 22.
    Martino R, Iacobelli S, Brand R, et al. (2006) Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 108: 836–846PubMedCrossRefGoogle Scholar
  23. 23.
    McSweeney PA, Niederwieser D, Shizuru JA, et al. (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft versus tumor effects. Blood 97: 3390–3400PubMedCrossRefGoogle Scholar
  24. 24.
    Morris E, Thomson K, Craddock C, et al. (2004) Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 104: 3865–3871PubMedCrossRefGoogle Scholar
  25. 25.
    Mohty M, Avinens O, Faucher C, et al. (2007) Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. Haematologica 92: 1004–1006PubMedCrossRefGoogle Scholar
  26. 26.
    Mohty M, Bay JO, Faucher C, et al. (2003) Graft versus host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 102: 470–476PubMedCrossRefGoogle Scholar
  27. 27.
    Mohty M, Boiron JM, Damaj G, et al. (2004) Graft versus myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 34: 77–84PubMedCrossRefGoogle Scholar
  28. 28.
    Mohty M, Kuentz M, Michallet M, et al. (2002) Chronic graft versus host disease after allogeneic blood stem cell transplantation: long term results of a randomized study. Blood 100: 3128–3134PubMedCrossRefGoogle Scholar
  29. 29.
    Mohty M, Nagler A, Killmann NM (2006) Reduced-intensity conditioning allogeneic stem cell transplantation: hype, reality or time for a rethink? Leukemia 20: 1653–1654PubMedCrossRefGoogle Scholar
  30. 30.
    Sayer HG, Kroger M, Beyer J, et al. (2003) Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 31: 1089–1095PubMedCrossRefGoogle Scholar
  31. 31.
    Schmid C, Schleuning M, Ledderose G, et al. (2005) Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 23: 5675–5687PubMedCrossRefGoogle Scholar
  32. 32.
    Shaw BE, Russell NH, Devereux S, et al. (2005) The impact of donor factors on primary non-engraftment in recipients of reduced intensity conditioned transplants from unrelated donors. Haematologica 90: 1562–1569PubMedGoogle Scholar
  33. 33.
    Sorror ML, Maris MB, Sandmaier BM, et al. (2005) Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 23: 3819–3829PubMedCrossRefGoogle Scholar
  34. 34.
    Sorror ML, Maris MB, Storb R, et al. (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106: 2912–2919PubMedCrossRefGoogle Scholar
  35. 35.
    Spitzer TR, McAfee S, Sackstein R, et al. (2000) Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 6: 309–320PubMedCrossRefGoogle Scholar
  36. 36.
    Stelljes M, Bornhauser M, Kroger M, et al. (2005) Conditioning with 8 Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Blood 106: 3314–3321PubMedCrossRefGoogle Scholar
  37. 37.
    Storb R, Yu C, Barnett T, et al. (1999) Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosupression after marrow transplantation. Blood 94: 1131–1136PubMedGoogle Scholar

Copyright information

© Springer Verlag France 2007

Authors and Affiliations

  1. 1.Inserm UMR U601, service d’hématologie clinique, hôpital Hôtel-Dieu, CHU de NantesUniversité de NantesNantes cedex 01France

Personalised recommendations